{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=43",
    "query": {
      "condition": "Resolution",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1357,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resolution&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T05:17:08.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06267274",
      "title": "A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost Ophthalmic Solution, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "LUMIGAN® (bimatoprost ophthalmic solution) 0.01%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amneal Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2024-04-01",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06267274"
    },
    {
      "nct_id": "NCT04883996",
      "title": "A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hyperopia",
        "Myopia"
      ],
      "interventions": [
        {
          "name": "1% EXP039",
          "type": "DRUG"
        },
        {
          "name": "Saline control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Canyon City Eyecare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2020-12-01",
      "completion_date": "2021-08-30",
      "has_results": false,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Azusa, California",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883996"
    },
    {
      "nct_id": "NCT03468855",
      "title": "A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vitiligo"
      ],
      "interventions": [
        {
          "name": "ATI-50002 topical solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2018-03-19",
      "completion_date": "2019-10-16",
      "has_results": true,
      "last_update_posted_date": "2020-11-30",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 5,
      "location_summary": "Encinitas, California • Los Angeles, California • Worcester, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468855"
    },
    {
      "nct_id": "NCT06017687",
      "title": "Data Collection and Evaluation of OptiBP Under Investigational Use",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "General Population"
      ],
      "interventions": [
        {
          "name": "OptiBP Study app",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Biospectal",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500000,
      "start_date": "2023-09-28",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Truckee, California",
      "locations": [
        {
          "city": "Truckee",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06017687"
    },
    {
      "nct_id": "NCT04814693",
      "title": "Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Pancreatitis",
        "Necrosis; Pancreas, Acute (Infectious)"
      ],
      "interventions": [
        {
          "name": "EndoRotor® System (Interscope, Inc., Northbridge, MA USA),",
          "type": "DEVICE"
        },
        {
          "name": "Conventional endoscopic devices (according to standards of care)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Erasmus Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-09-02",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04814693"
    },
    {
      "nct_id": "NCT02667236",
      "title": "A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seborrheic Keratosis"
      ],
      "interventions": [
        {
          "name": "A-101 Solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2016-01",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-02-06",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Malvern, Pennsylvania",
      "locations": [
        {
          "city": "Malvern",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02667236"
    },
    {
      "nct_id": "NCT03032809",
      "title": "Magnetic Resonance Imaging of Intracranial Vasculopathies",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "CNS Vasculitis"
      ],
      "interventions": [
        {
          "name": "Vessel Wall MR imaging",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-09",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2018-09-17",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03032809"
    },
    {
      "nct_id": "NCT00706433",
      "title": "Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "aminolevulinic acid HCL (ALA)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (VEH)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "DUSA Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2007-03",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2011-10-24",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 14,
      "location_summary": "Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00706433"
    },
    {
      "nct_id": "NCT02432157",
      "title": "Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Subarachnoid Hemorrhage",
        "Cerebral Vasospasm",
        "Hyponatremia"
      ],
      "interventions": [
        {
          "name": "HTS 3%",
          "type": "DRUG"
        },
        {
          "name": "Standard fluid management",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2015-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-02-11",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432157"
    },
    {
      "nct_id": "NCT06721871",
      "title": "Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Microvillus Inclusion Disease",
        "Congenital Disorders",
        "Rare Diseases"
      ],
      "interventions": [
        {
          "name": "Crofelemer Powder for Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Powder for Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Napo Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2025-05-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-29T05:17:08.773Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721871"
    }
  ]
}